» Articles » PMID: 31755099

Hormone-related Diseases and Prostate Cancer: An English National Record Linkage Study

Overview
Journal Int J Cancer
Specialty Oncology
Date 2019 Nov 23
PMID 31755099
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Insulin-like growth factor-I (IGF-I) and testosterone may be related to prostate cancer risk. Acromegaly is associated with clinically high IGF-I concentrations. Klinefelter's syndrome, testicular hypofunction and hypopituitarism are associated with clinically low testosterone concentrations. We aimed to investigate whether diagnosis with these conditions was associated with subsequent prostate cancer diagnosis and mortality. We used linked English national Hospital Episode Statistics and mortality data from 1999 to 2017 to construct and follow-up cohorts of men aged ≥35 years diagnosed with (i) acromegaly (n = 2,495) and (ii) hypogonadal-associated diseases (n = 18,763): Klinefelter's syndrome (n = 1,992), testicular hypofunction (n = 8,086) and hypopituitarism (n = 10,331). We estimated adjusted hazard ratios (HRs) and confidence intervals (CIs) for prostate cancer diagnosis and death using Cox regression in comparison with an unexposed reference cohort of 4.3 million men, who were admitted to hospital for a range of minor surgeries and conditions (n observed cases = 130,000, n prostate cancer deaths = 30,000). For men diagnosed with acromegaly, HR for prostate cancer diagnosis was 1.33 (95% CI 1.09-1.63; p = 0.005; n observed cases = 96), HR for prostate cancer death was 1.44 (95% CI 0.92-2.26; p = 0.11; n deaths = 19). Diagnosis with Klinefelter's syndrome was associated with a lower prostate cancer risk (HR = 0.58, 95% CI 0.37-0.91; p = 0.02; n observed cases = 19) and hypopituitarism was associated with a reduction in prostate cancer death (HR = 0.53, 95% CI 0.35-0.79; p = 0.002; n deaths = 23). These results support the hypothesised roles of IGF-I and testosterone in prostate cancer development and/or progression. These findings are important because they provide insight into prostate cancer aetiology.

Citing Articles

Periprostatic Adipose Tissue as a Contributor to Prostate Cancer Pathogenesis: A Narrative Review.

Drewa J, Lazar-Juszczak K, Adamowicz J, Juszczak K Cancers (Basel). 2025; 17(3).

PMID: 39941741 PMC: 11816168. DOI: 10.3390/cancers17030372.


From pituitary cells to prostate gland in health and disease: direct and indirect endocrine connections.

Sarmento-Cabral A, Fuentes-Fayos A, Ordonez F, Leon-Gonzalez A, Martinez-Fuentes A, Gahete M Rev Endocr Metab Disord. 2025; .

PMID: 39910005 DOI: 10.1007/s11154-025-09948-7.


Obesity, dietary interventions and microbiome alterations in the development and progression of prostate cancer.

Trecarten S, Liss M, Hamilton-Reeves J, DiGiovanni J Front Immunol. 2025; 15():1448116.

PMID: 39840030 PMC: 11747771. DOI: 10.3389/fimmu.2024.1448116.


IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer.

Ravi P, Wang V, Fichorova R, McGregor B, Wei X, Basaria S Endocr Relat Cancer. 2023; 30(11).

PMID: 37671811 PMC: 11304032. DOI: 10.1530/ERC-23-0241.


Potential role of gut microbiota in prostate cancer: immunity, metabolites, pathways of action?.

Zha C, Peng Z, Huang K, Tang K, Wang Q, Zhu L Front Oncol. 2023; 13:1196217.

PMID: 37265797 PMC: 10231684. DOI: 10.3389/fonc.2023.1196217.


References
1.
De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce A, Warner T . Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology. 2018; 91(2):e139-e142. DOI: 10.1212/WNL.0000000000005771. View

2.
Snyder P, Bhasin S, Cunningham G, Matsumoto A, Stephens-Shields A, Cauley J . Lessons From the Testosterone Trials. Endocr Rev. 2018; 39(3):369-386. PMC: 6287281. DOI: 10.1210/er.2017-00234. View

3.
Draisma G, Boer R, Otto S, van der Cruijsen I, Damhuis R, Schroder F . Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003; 95(12):868-78. DOI: 10.1093/jnci/95.12.868. View

4.
Dal J, Leisner M, Hermansen K, Farkas D, Bengtsen M, Kistorp C . Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature. J Clin Endocrinol Metab. 2018; 103(6):2182-2188. DOI: 10.1210/jc.2017-02457. View

5.
Thompson Jr I, Goodman P, Tangen C, Parnes H, Minasian L, Godley P . Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013; 369(7):603-10. PMC: 4141537. DOI: 10.1056/NEJMoa1215932. View